Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schiff

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Anaesthesia|April 12, 2013
Veno-venous extracorporeal membrane oxygenation (ECMO) support during anaesthesia for oesophagectomyJ H Schiff, J Köninger, J Teschner, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
ARHGEF7 S-glutathionylation promotes cancer cell migration through Rac1 activationWilliam H Schiff, Madhu C Shivamadhu, Faezeh Mashhadi Ramezani, et al.
Arthritis and Rheumatism|June 26, 2008
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyMichael E Weinblatt, Michael H Schiff, Eric M Ruderman, et al.
Annals of the Rheumatic Diseases|January 28, 2006
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisM H Schiff, G R Burmester, J D Kent, et al.
Journal of Molecular Medicine (Berlin, Germany)|November 3, 2001
Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinomaM Volkmann, J H Schiff, Y Hajjar, et al.
The Journal of Rheumatology|May 17, 2011
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson, Allan Gibofsky, William R Palmer, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Rheumatology (Oxford, England)|February 22, 2003
A simplified disease activity index for rheumatoid arthritis for use in clinical practiceJ S Smolen, F C Breedveld, M H Schiff, et al.
British Journal of Anaesthesia|May 8, 2014
Major incidents and complications in otherwise healthy patients undergoing elective procedures: results based on 1.37 million anaesthetic proceduresJ H Schiff, A Welker, B Fohr, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Anaesthesia|April 12, 2013
Veno-venous extracorporeal membrane oxygenation (ECMO) support during anaesthesia for oesophagectomyJ H Schiff, J Köninger, J Teschner, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
ARHGEF7 S-glutathionylation promotes cancer cell migration through Rac1 activationWilliam H Schiff, Madhu C Shivamadhu, Faezeh Mashhadi Ramezani, et al.
Arthritis and Rheumatism|June 26, 2008
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyMichael E Weinblatt, Michael H Schiff, Eric M Ruderman, et al.
Annals of the Rheumatic Diseases|January 28, 2006
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisM H Schiff, G R Burmester, J D Kent, et al.
Journal of Molecular Medicine (Berlin, Germany)|November 3, 2001
Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinomaM Volkmann, J H Schiff, Y Hajjar, et al.
The Journal of Rheumatology|May 17, 2011
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson, Allan Gibofsky, William R Palmer, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Rheumatology (Oxford, England)|February 22, 2003
A simplified disease activity index for rheumatoid arthritis for use in clinical practiceJ S Smolen, F C Breedveld, M H Schiff, et al.
British Journal of Anaesthesia|May 8, 2014
Major incidents and complications in otherwise healthy patients undergoing elective procedures: results based on 1.37 million anaesthetic proceduresJ H Schiff, A Welker, B Fohr, et al.
Pageof 8